Medical Nursing Relieve Moderation

Question: Describe about the Medical Nursing for Relieve Moderation. Answer: Endone is a narcotic painkiller that is used to relieve moderate or severe pain such as after surgery or injury. The name is actually the brand nomenclature for a medicine containing the active ingredient oxycodone hydrochloride. Endone belongs to the Schedule 8 Drugs designated as drugs of addiction. Schedule 8 drugs or drugs of dependence are prescription medicines possessing a well established therapeutic need along with relatively high risk of misuse, abuse and dependence. The categorization of the medicines of this group ensures that the patients have the necessary access to effective treatment while the chance for misuse is mitigated and the development of dependence is eliminated as well (www.health.nsw.gov.au., 2016). Taking Endone medication can lead to a range of side effects ranging from mild, moderate and severe symptoms. Some of the effects are considered as quite grave requiring medical supervision and adequate clinical attention. Early and timely consultation with the physician may prevent further complication. Prompt adjustment in therapeutic intervention might benefit the patient. Hence knowledge pertinent to the storage requirement for this drug within a healthcare setting is essential to procure optimum outcome. Endone tablets are required to be stored in appropriate container until actual consumption and preferably in a cool, dry place with temperature below 30?C. Heat and dampness can spoil certain medicines and Endone is one such drug that needs to be protected from these damaging factors. A lock cupboard located one and a half meters above the ground has been suggested as a suitable place to store this medicine (www.nps.org.au., 2016). According to the National in patients medication chart guidelines, the 7 essential elements that must be documented on a medication order by the doctor have been suggested. The patients identification details require to be completed in every medication chart. All the medication chart should be completed and encompass certain basic details comprising of the date in which it has been prescribed, route of administration, generic drug name, dose suggested in metric units and Arabic numerals, frequency of administration utilizing only accepted abbreviations, timings at which the drug is administered with the entry by the medical officer. Further, the chart should comprise medical officers signature and medical officers name printed. In case of knowledge for adverse drug reaction (ADR) to the prescribed medicine, abstinence from taking that medication is recommended. Without prior consent from the doctor, it is advisable not to withhold the medicines for patients who are in pre-operative s tate or nil by mouth or fasting condition (www.healthywa.wa.gov.au., 2016). Further implications for the medication chart have been suggested by the NIMC where the section that cannot be altered without authorized approval from the national sector has been highlighted. This include the information concerning the patient identification, numbering of the chart, cautions relating to allergies and adverse drug reactions, single use and nurse initiated medicines and pre-medications, telephonic orders, medicines consumed before admission to hospital, regular medications information, documentation of patient weight and height, folds and facts about PRN or as required medicines (www.safetyandquality.gov.au., 2016). Thus the medication chart must be in line with the current guidelines and recommendations. Reviewing of 71 year old Mrs. As condition it was found that she was suffering from chronic heart failure and osteoarthritis that prompted her to take medication regime consisting of Frusemide and Digoxin tablet along with Mylanta suspension each having separate functioning. The Frusemide drug acts as a loop diuretic to treat edema pertaining to cardiovascular disease. Digoxin acts by means of making the heart beats stronger and regularizing the rhythm of heart. Mylanta serves the purpose of treating too much acid in the stomach thereby addressing heart burns, acid indigestion and stomach upset. It is generally available as the over the counter acid neutralizing medication. The vital problem of chronic heart failure disorder as well as the gatroesophageal reflux disease (GERD) thus may be effectively resolved by administering these specific medications that might alleviate the ensuing symptoms (Gaumnitz, 2012). However drug interactions between the prescribed medicines might be a pos sibility in certain cases. Moderate drug interaction might occur following consumption of Frusemide and Digoxin and patient must pay proper attention to symptoms of fatigue, muscle cramps and pain, nausea, declined appetite, visual problems or irregular heartbeats. Prolonged use of Frusemide and Mylanta drug combination might further lead to moderate drug interaction thereby accentuating the risk of dehydration and electrolyte imbalance. Symptoms for depletion of fluid and electrolyte might account for dizziness, lightheadedness, dry throat, muscle pain, fatigue, reduced urination and palpitation (Upfal, 2006). Hence post medication, the symptoms for any adverse drug reaction in the patient must be carefully monitored. References Gaumnitz, E. A. (2012). Pharmacologic Treatment of GERD. InGastroesophageal Reflux and the Lung(pp. 227-247). Springer New York. Upfal, J. (2006). Australian drug guide. Black Inc. www.safetyandquality.gov.au., (2016). Retrieved on 1 December 2016, from https://safetyandquality.gov.au/wp-content/uploads/2012/02/7439-NIMC-Local-Management-Guidelines.pdf www.health.nsw.gov.au., (2016). Retrieved on 1 December 2016, from https://www.health.nsw.gov.au/pharmaceutical/Documents/drugsofaddiction-sch8.pdf www.nps.org.au., (2016). Retrieved on 1 December 2016, from https://www.nps.org.au/medicines/pain-relief/opioid-pain-relievers/oxycodone-hydrochloride/endone-tablets www.healthywa.wa.gov.au., (2016). Retrieved on 1 December 2016, from https://www.healthywa.wa.gov.au/~/media/Files/Corporate/general%20documents/Quality/PDF/NIMC-WAGuidelines2012.ashx